To investigate the role of Pcsk5 in pancreatic carcinogenesis and to evaluate its utility as a therapeutic target for pancreatic cancer therapy, we employed a commercially available and effective general PCs inhibitor, CMK (decanoyl-Arg-Val-Lys-Arg-chloromethlketone), which has been successfully used to suppress growth of certain cancer types (58, 59, 61, 66, 67) but not yet tested in PDAC. The gene discussed is CNTN3; the disease is pancreatic neoplasm.